Literature DB >> 33336731

Long noncoding RNA MAFG-AS1 facilitates the progression of hepatocellular carcinoma via targeting miR-3196/OTX1 axis.

Z-Q Hu1, H-C Li, F Teng, Q-M Chang, X-B Wu, J-F Feng, Z-P Zhang.   

Abstract

OBJECTIVE: Hepatocellular carcinoma (HCC) is an invasive malignant tumor with high mortality rate. Long non-coding RNA (lncRNA) MAFG-AS1 has been showed to play an oncogenic role in several malignant tumors. Nonetheless, the exact role of MAFG-AS1 in the progression of HCC has not been fully elucidated. PATIENTS AND METHODS: Real-time quantitative polymerase chain reaction (RT-qPCR) and Western blot were used to detect the mRNA and protein expression of MAFG-AS1 in HCC tissues and cells. Cell counting kit-8 (CCK-8), transwell and tubule formation assays were applied to uncover the proliferation, migration, invasion and tumor angiogenesis of HCC cells, respectively. RNA binding protein immunoprecipitation (RIP) assay and Luciferase reporter gene assay were employed to explore the molecular mechanism. In addition, Xenograft assay was used to investigate the effect of MAFG-AS1 in vivo.
RESULTS: MAFG-AS1 was highly expressed in HCC tissues and cells. Attenuation of MAFG-AS1 evidently suppressed the proliferation, migration, invasion and tumor angiogenesis of HCC cells, suggesting that MAFG-AS1 played an oncogenic role in HCC. MiR-3196 was sponged by MAFG-AS1, and OTX1 was a downstream target of miR-3196 in HCC. In addition, OTX1 expression was negatively associated with miR-3196 but positively associated with MAFG-AS1 in HCC tissues. Overexpression of OTX1 could abolish the repressive influence of MAFG-AS1 inhibition on the proliferation, migration, invasion and tumor angiogenesis of HCC cells.
CONCLUSIONS: MAFG-AS1 facilitated the progression of HCC via targeting miR-3196/OTX1 axis, which might be used as a new insight for HCC treatment.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33336731     DOI: 10.26355/eurrev_202012_24002

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

1.  A Co-Expression Network Reveals the Potential Regulatory Mechanism of lncRNAs in Relapsed Hepatocellular Carcinoma.

Authors:  Yuan Fang; Yang Yang; XiaoLi Zhang; Na Li; Bo Yuan; Li Jin; Sheng Bao; MengGe Li; Dan Zhao; LingRui Li; Zhong Zeng; HanFei Huang
Journal:  Front Oncol       Date:  2021-08-31       Impact factor: 6.244

2.  A Novel Nine-lncRNA Risk Signature Correlates With Immunotherapy in Hepatocellular Carcinoma.

Authors:  Ye Nie; Jianhui Li; Wenlong Wu; Dongnan Guo; Xinjun Lei; Tianchen Zhang; Yanfang Wang; Zhenzhen Mao; Xuan Zhang; Wenjie Song
Journal:  Front Oncol       Date:  2021-09-15       Impact factor: 6.244

Review 3.  S-Adenosylmethionine: From the Discovery of Its Inhibition of Tumorigenesis to Its Use as a Therapeutic Agent.

Authors:  Rosa M Pascale; Maria M Simile; Diego F Calvisi; Claudio F Feo; Francesco Feo
Journal:  Cells       Date:  2022-01-25       Impact factor: 6.600

4.  MAFG-AS1 is a prognostic biomarker and facilitates prostate cancer progression.

Authors:  Peizhang Li; Yuanping Shi; Miaomiao Guo; Huan Xu; Ming Zhan; Zhong Wang; Yanbo Chen
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

5.  Long Non-Coding RNA MAFG-AS1 as a Potential Biomarker for Hepatocellular Carcinoma: Linkage with Tumor Features, Markers, Liver Functions, and Survival Profile.

Authors:  Yuanyuan Tian; Jiao Wang; Ge Tian; Bing Li; Moli Chen; Xiaoning Sun
Journal:  Front Surg       Date:  2022-05-17

6.  OTX1 promotes tumorigenesis and progression of cervical cancer by regulating the Wnt signaling pathway.

Authors:  Limin Zhou; Hongying Li; Dunlan Zhang; Lu Chen; Hong Dong; Yuqin Yuan; Tinghui Wang
Journal:  Oncol Rep       Date:  2022-09-30       Impact factor: 4.136

Review 7.  The Role of LSD1 and LSD2 in Cancers of the Gastrointestinal System: An Update.

Authors:  Gianluca Malagraba; Mahdieh Yarmohammadi; Aadil Javed; Carles Barceló; Teresa Rubio-Tomás
Journal:  Biomolecules       Date:  2022-03-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.